Browse studies
Find your next paid study
3 recruiting studies matching your filters
Phase 2
A Phase 2, Single-Arm Trial of Relacorilant in Combination With Nab-Paclitaxel and Gemcitabine in Chemotherapy-Naïve Patients With Metastatic Pancreatic Adenocarcinoma (TRIDENT)
This is a 2-part, Phase 2 study to evaluate the safety, tolerability, dosing, pharmacokinetics (PK), and efficacy of relacorilant in combination with nab-pacli…
AdenocarcinomaCarcinoma, Pancreatic Ductal
Estimated
~$10 – $8,750
Corcept TherapeuticsNCT07259317
Phase 2
A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU…
Adenocarcinoma, Pancreatic Ductal
Estimated
~$10 – $8,750
Genentech, Inc.NCT05968326
Phase 1
A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene
The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This st…
Carcinoma, Pancreatic DuctalColorectal NeoplasmsCarcinoma, Non-Small-Cell Lung
Estimated
~$10 – $7,500
PfizerNCT06447662